Since joining 3SBio in June 2007, Dr Chen has been responsible for developing long-range growth strategies and pursuing strategic business opportunities and external alliances with biotechnology and pharmaceutical companies in major markets worldwide. In addition to his existing responsibilities, Dr Chen will assume oversight of commercial operations including commercial strategy, medical and regulatory, government affairs, and export. He will be based in Beijing, China.
Prior to joining 3SBio, Dr Chen held various managerial positions in the US pharmaceutical industry, including business development, sales and marketing, market research, new product development and R&D portfolio management both with Eli Lilly and GlaxoSmithKline.
Jing Lou, CEO of 3SBio, said: “I am very pleased to announce the promotion of David Chen to the position of COO. His in-depth understanding of the Chinese pharmaceutical market place combined with his significant operating experience with multinational pharmaceutical companies in the US make him the ideal candidate to assume this newly created position.”